2seventy bio, Inc. (TSVT)

Market Cap	134.65M
Revenue (ttm)	45.62M
Net Income (ttm)	-94.55M
Shares Out	51.59M
EPS (ttm)	-1.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	308,568
Open	2.660
Previous Close	2.680
Day's Range	2.502 - 2.700
52-Week Range	2.290 - 6.000
Beta	1.75
Analysts	Buy
Price Target	8.50 (+225.67%)
Earnings Date	Mar 4, 2025

About TSVT

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company’s products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Employees: 274
• Stock Exchange: NASDAQ
• Ticker Symbol: TSVT
• Website: https://www.2seventybio.com

Financial Performance

In 2023, 2seventy bio's revenue was $100.39 million, an increase of 9.72% compared to the previous year's $91.50 million. Losses were -$217.57 million, -14.39% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for TSVT stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 225.67% from the latest price.

Price Target

$8.5

(225.67% upside)

Analyst Consensus: Buy